We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 22, 2021

FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J. Clin. Oncol 2021 Feb 08;[EPub Ahead of Print], JR Hecht, S Lonardi, J Bendell, HW Sim, T Macarulla, CD Lopez, E Van Cutsem, AJ Muñoz Martin, JO Park, R Greil, H Wang, RR Hozak, I Gueorguieva, Y Lin, S Rao, BY Ryoo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading